Recombinant Aflibercept Biosimilar antibody

Catalog No. ABIN7795087

The Mouse Monoclonal anti-Aflibercept Biosimilar antibody (ABIN7795087) specifically detects Aflibercept Biosimilar in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant Aflibercept Biosimilar antibody (ABIN7795087)

Target: Aflibercept Biosimilar

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details

Expression System: Mammalian cells

Purpose: Aflibercept Biosimilar

Characteristics: What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons ( kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details

Target: Aflibercept Biosimilar

Target Type: Biosimilar